JP2007513197A - 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 - Google Patents
統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 Download PDFInfo
- Publication number
- JP2007513197A JP2007513197A JP2006543635A JP2006543635A JP2007513197A JP 2007513197 A JP2007513197 A JP 2007513197A JP 2006543635 A JP2006543635 A JP 2006543635A JP 2006543635 A JP2006543635 A JP 2006543635A JP 2007513197 A JP2007513197 A JP 2007513197A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- indan
- benzo
- piperazin
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims description 206
- 201000000980 schizophrenia Diseases 0.000 title claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 17
- 125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 69
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 100
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 208000035475 disorder Diseases 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 208000028017 Psychotic disease Diseases 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 239000003176 neuroleptic agent Substances 0.000 claims description 24
- 230000000701 neuroleptic effect Effects 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 208000019901 Anxiety disease Diseases 0.000 claims description 18
- 208000016285 Movement disease Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- 208000023105 Huntington disease Diseases 0.000 claims description 17
- 208000020401 Depressive disease Diseases 0.000 claims description 16
- 208000012661 Dyskinesia Diseases 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 230000036506 anxiety Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 208000020925 Bipolar disease Diseases 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 206010012289 Dementia Diseases 0.000 claims description 13
- 230000003542 behavioural effect Effects 0.000 claims description 13
- 208000024714 major depressive disease Diseases 0.000 claims description 13
- 208000024732 dysthymic disease Diseases 0.000 claims description 12
- 208000015238 neurotic disease Diseases 0.000 claims description 12
- 206010016275 Fear Diseases 0.000 claims description 11
- SDXGJZJPPHVJAL-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(C4=CC=3)(C)C)NC(=O)C)=NSC2=C1 SDXGJZJPPHVJAL-UHFFFAOYSA-N 0.000 claims description 11
- 208000027534 Emotional disease Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- RSCDOMZKFHQDSH-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(C(C4=C3)(C)C)NC(=O)C)=NSC2=C1 RSCDOMZKFHQDSH-UHFFFAOYSA-N 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 10
- 208000008811 Agoraphobia Diseases 0.000 claims description 9
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 9
- 206010013663 drug dependence Diseases 0.000 claims description 9
- 208000019022 Mood disease Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 206010012335 Dependence Diseases 0.000 claims description 7
- 208000019568 Shared Paranoid disease Diseases 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940005513 antidepressants Drugs 0.000 claims description 7
- 208000028683 bipolar I disease Diseases 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 230000000306 recurrent effect Effects 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000000044 Amnesia Diseases 0.000 claims description 6
- 208000031091 Amnestic disease Diseases 0.000 claims description 6
- 206010003805 Autism Diseases 0.000 claims description 6
- 208000020706 Autistic disease Diseases 0.000 claims description 6
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 206010012218 Delirium Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
- 206010073211 Postural tremor Diseases 0.000 claims description 6
- 201000000552 Scott syndrome Diseases 0.000 claims description 6
- 206010039966 Senile dementia Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 6
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 230000006986 amnesia Effects 0.000 claims description 6
- 239000002249 anxiolytic agent Substances 0.000 claims description 6
- 230000000949 anxiolytic effect Effects 0.000 claims description 6
- 229940049706 benzodiazepine Drugs 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000010118 dystonia Diseases 0.000 claims description 6
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000000698 schizophrenic effect Effects 0.000 claims description 6
- 208000018198 spasticity Diseases 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 208000027099 Paranoid disease Diseases 0.000 claims description 5
- 206010038743 Restlessness Diseases 0.000 claims description 5
- 208000028810 Shared psychotic disease Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 4
- 206010008748 Chorea Diseases 0.000 claims description 4
- 206010012239 Delusion Diseases 0.000 claims description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000004547 Hallucinations Diseases 0.000 claims description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
- 206010022998 Irritability Diseases 0.000 claims description 4
- 208000036626 Mental retardation Diseases 0.000 claims description 4
- 206010034158 Pathological gambling Diseases 0.000 claims description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 4
- 208000027465 Psychotic Affective disease Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 4
- 208000012826 adjustment disease Diseases 0.000 claims description 4
- 208000025748 atypical depressive disease Diseases 0.000 claims description 4
- 208000030963 borderline personality disease Diseases 0.000 claims description 4
- 231100000868 delusion Toxicity 0.000 claims description 4
- 229960002069 diamorphine Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 206010020765 hypersomnia Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- WZKYRBHMAAHXNT-NRFANRHFSA-N n-[(2s)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)NC(=O)C)=NSC2=C1 WZKYRBHMAAHXNT-NRFANRHFSA-N 0.000 claims description 4
- ACZCVZUKGWGYJX-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-1-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CCC(C4=C3)NC(=O)C)=NSC2=C1 ACZCVZUKGWGYJX-UHFFFAOYSA-N 0.000 claims description 4
- 208000025319 neurotic depression Diseases 0.000 claims description 4
- 229960002715 nicotine Drugs 0.000 claims description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002695 phenobarbital Drugs 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 206010068631 Childhood depression Diseases 0.000 claims description 3
- 201000009916 Postpartum depression Diseases 0.000 claims description 3
- 206010037213 Psychomotor retardation Diseases 0.000 claims description 3
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 3
- 206010041247 Social fear Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000013200 Stress disease Diseases 0.000 claims description 3
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 3
- 206010068932 Terminal insomnia Diseases 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000022257 bipolar II disease Diseases 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000001932 seasonal effect Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 208000016261 weight loss Diseases 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 201000003995 melancholia Diseases 0.000 claims description 2
- HDAMSHRAOONPCR-JOCHJYFZSA-N n-[(2r)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]-n-methylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@H](CC4=C3)N(C)C(C)=O)=NSC2=C1 HDAMSHRAOONPCR-JOCHJYFZSA-N 0.000 claims description 2
- HDAMSHRAOONPCR-QFIPXVFZSA-N n-[(2s)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]-n-methylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)N(C)C(C)=O)=NSC2=C1 HDAMSHRAOONPCR-QFIPXVFZSA-N 0.000 claims description 2
- VFPPQTMROBVISM-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-yl]-n-methylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C(C)(C)C(C(C4=C3)(C)C)N(C)C(C)=O)=NSC2=C1 VFPPQTMROBVISM-UHFFFAOYSA-N 0.000 claims description 2
- ULMXAOBOSPKBRB-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C(C)(C)C(C(C4=C3)(C)C)NC(=O)C)=NSC2=C1 ULMXAOBOSPKBRB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims 2
- RETSQNCHXAKEGO-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n,1,1,3,3-pentamethyl-2h-inden-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C(C)(C)C(C(C4=C3)(C)C)NC)=NSC2=C1 RETSQNCHXAKEGO-UHFFFAOYSA-N 0.000 claims 1
- 206010012206 Delayed recovery from anaesthesia Diseases 0.000 claims 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- NAMVXIDCEILDRZ-OAQYLSRUSA-N n-[(2r)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]propanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@H](CC4=C3)NC(=O)CC)=NSC2=C1 NAMVXIDCEILDRZ-OAQYLSRUSA-N 0.000 claims 1
- RYSKOGQLCQPXTH-QFIPXVFZSA-N n-[(2s)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]cyclopropanecarboxamide Chemical compound N([C@@H]1CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2C1)C(=O)C1CC1 RYSKOGQLCQPXTH-QFIPXVFZSA-N 0.000 claims 1
- NAMVXIDCEILDRZ-NRFANRHFSA-N n-[(2s)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]propanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)NC(=O)CC)=NSC2=C1 NAMVXIDCEILDRZ-NRFANRHFSA-N 0.000 claims 1
- 102000045222 parkin Human genes 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 209
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 203
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 180
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 148
- -1 heterocyclic piperazine derivatives Chemical class 0.000 description 116
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 104
- 239000000243 solution Substances 0.000 description 103
- 235000019439 ethyl acetate Nutrition 0.000 description 88
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 84
- 238000006243 chemical reaction Methods 0.000 description 83
- 239000000203 mixture Substances 0.000 description 83
- 239000007787 solid Substances 0.000 description 71
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- 239000011541 reaction mixture Substances 0.000 description 59
- 239000000460 chlorine Substances 0.000 description 58
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
- 239000011734 sodium Substances 0.000 description 56
- 239000012267 brine Substances 0.000 description 55
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 55
- 239000002904 solvent Substances 0.000 description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 239000000741 silica gel Substances 0.000 description 45
- 229910002027 silica gel Inorganic materials 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 42
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 36
- 238000004587 chromatography analysis Methods 0.000 description 35
- 239000012458 free base Substances 0.000 description 35
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
- 238000004128 high performance liquid chromatography Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 29
- 238000010992 reflux Methods 0.000 description 28
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 239000010410 layer Substances 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 20
- 238000001914 filtration Methods 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 235000011181 potassium carbonates Nutrition 0.000 description 10
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 9
- 239000012346 acetyl chloride Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 150000003840 hydrochlorides Chemical class 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 7
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 238000004296 chiral HPLC Methods 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 235000009518 sodium iodide Nutrition 0.000 description 7
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 6
- 0 *1c2ccccc2C1*1CCNCC1 Chemical compound *1c2ccccc2C1*1CCNCC1 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 5
- XVFJKYPFHFHIOV-UHFFFAOYSA-N 1-methyl-1,3-dihydroinden-2-one Chemical compound C1=CC=C2C(C)C(=O)CC2=C1 XVFJKYPFHFHIOV-UHFFFAOYSA-N 0.000 description 5
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 5
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000005587 bubbling Effects 0.000 description 5
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- KBFUPRLHCWUTGK-UHFFFAOYSA-N 1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)C(C)(C)C2=C1 KBFUPRLHCWUTGK-UHFFFAOYSA-N 0.000 description 4
- YRCWRCUGSVKMLI-UHFFFAOYSA-N 2-[5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2H-inden-2-yl]-1H-inden-1-amine Chemical compound CC1(C(C(C2=C1C=CC(=C2)CCN3CCN(CC3)C4=NOC5=CC=CC=C54)(C)C)C6=CC7=CC=CC=C7C6N)C YRCWRCUGSVKMLI-UHFFFAOYSA-N 0.000 description 4
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 4
- QWZAOSKLFKAEOK-UHFFFAOYSA-N 3,3-dimethyl-2h-inden-1-one Chemical compound C1=CC=C2C(C)(C)CC(=O)C2=C1 QWZAOSKLFKAEOK-UHFFFAOYSA-N 0.000 description 4
- XRDCLLACPRPEMB-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,1,3,3-tetramethylinden-2-one Chemical compound ClCC(=O)C1=CC=C2C(C)(C)C(=O)C(C)(C)C2=C1 XRDCLLACPRPEMB-UHFFFAOYSA-N 0.000 description 4
- GTMQVASEMHDCKU-UHFFFAOYSA-N 5-(2-chloroethyl)-2,3-dihydro-1H-inden-2-amine Chemical compound C1=C(CCCl)C=C2CC(N)CC2=C1 GTMQVASEMHDCKU-UHFFFAOYSA-N 0.000 description 4
- ULKDUEAMNQRFDT-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-chloropropyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(Cl)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NSC2=C1 ULKDUEAMNQRFDT-UHFFFAOYSA-N 0.000 description 4
- MGKBOARNIKJYBV-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propanoyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(=O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 MGKBOARNIKJYBV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-methylmorpholine Substances CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 241001274216 Naso Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940005530 anxiolytics Drugs 0.000 description 4
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- BJOWSBJODJDOEY-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-2,2,2-trifluoroacetamide Chemical compound C1=CC=C2CC(NC(=O)C(F)(F)F)CC2=C1 BJOWSBJODJDOEY-UHFFFAOYSA-N 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- HVBHEPYJVAMWCY-UHFFFAOYSA-N 1,1-dimethylindene Chemical compound C1=CC=C2C(C)(C)C=CC2=C1 HVBHEPYJVAMWCY-UHFFFAOYSA-N 0.000 description 3
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- JYSNWEPTBXFJSP-UHFFFAOYSA-N 3,3-dimethyl-1,2-dihydroinden-1-ol Chemical compound C1=CC=C2C(C)(C)CC(O)C2=C1 JYSNWEPTBXFJSP-UHFFFAOYSA-N 0.000 description 3
- GUHBZTMKWQVBLU-UHFFFAOYSA-N 3,3-dimethyl-1h-inden-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)CC2=C1 GUHBZTMKWQVBLU-UHFFFAOYSA-N 0.000 description 3
- JTZZMXVIHNHASS-UHFFFAOYSA-N 3-methyl-3-phenylbutanoic acid Chemical compound OC(=O)CC(C)(C)C1=CC=CC=C1 JTZZMXVIHNHASS-UHFFFAOYSA-N 0.000 description 3
- DOQLJTKEUIJSKK-UHFFFAOYSA-N 3-piperazin-1-yl-1,2-benzothiazole;hydrochloride Chemical compound Cl.C1CNCCN1C1=NSC2=CC=CC=C12 DOQLJTKEUIJSKK-UHFFFAOYSA-N 0.000 description 3
- DPKKSXQKELJRAM-UHFFFAOYSA-N 5-(3-chloropropanoyl)-1,1,3,3-tetramethylinden-2-one Chemical compound ClCCC(=O)C1=CC=C2C(C)(C)C(=O)C(C)(C)C2=C1 DPKKSXQKELJRAM-UHFFFAOYSA-N 0.000 description 3
- MOSDVLLNFCABBB-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-chloropropyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(Cl)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 MOSDVLLNFCABBB-UHFFFAOYSA-N 0.000 description 3
- GRKLZMSTAZCABB-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-hydroxypropyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 GRKLZMSTAZCABB-UHFFFAOYSA-N 0.000 description 3
- NEAYEUUXOYYGML-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)N)=NSC2=C1 NEAYEUUXOYYGML-UHFFFAOYSA-N 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- AQJMXLBGRXTPGQ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroinden-2-yl)acetamide Chemical compound C1=CC=C2C(C)(C)C(NC(=O)C)CC2=C1 AQJMXLBGRXTPGQ-UHFFFAOYSA-N 0.000 description 3
- WZKYRBHMAAHXNT-OAQYLSRUSA-N n-[(2r)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@H](CC4=C3)NC(=O)C)=NSC2=C1 WZKYRBHMAAHXNT-OAQYLSRUSA-N 0.000 description 3
- CLOWCLCWKPDORE-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]-2,2,2-trifluoroacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)NC(=O)C(F)(F)F)=NSC2=C1 CLOWCLCWKPDORE-UHFFFAOYSA-N 0.000 description 3
- DYFAWUZVEPOIMN-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]-3-methylbutanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NC(=O)CC(C)C)=NSC2=C1 DYFAWUZVEPOIMN-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 239000004001 serotonin 1D antagonist Substances 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 3
- KFPVGYQEDPGWBS-UHFFFAOYSA-N 1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(C)(C)C(O)C(C)(C)C2=C1 KFPVGYQEDPGWBS-UHFFFAOYSA-N 0.000 description 2
- GIQQAQFTVJTULV-UHFFFAOYSA-N 1,3-oxazol-3-ium;chloride Chemical compound Cl.C1=COC=N1 GIQQAQFTVJTULV-UHFFFAOYSA-N 0.000 description 2
- ORECNKBJIMKZNX-UHFFFAOYSA-N 1,3-thiazol-3-ium;chloride Chemical compound Cl.C1=CSC=N1 ORECNKBJIMKZNX-UHFFFAOYSA-N 0.000 description 2
- DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CSWSNLOUPIZWNV-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-hydroxyethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 CSWSNLOUPIZWNV-UHFFFAOYSA-N 0.000 description 2
- QXRNLIIDLNEQEN-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n-ethyl-3,3-dimethyl-1,2-dihydroinden-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(C(C4=C3)(C)C)NCC)=NSC2=C1 QXRNLIIDLNEQEN-UHFFFAOYSA-N 0.000 description 2
- SASNRSIOWKPBAP-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-chloroethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(Cl)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 SASNRSIOWKPBAP-UHFFFAOYSA-N 0.000 description 2
- OFYHGYRKCBLLIJ-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-hydroxypropyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(O)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NSC2=C1 OFYHGYRKCBLLIJ-UHFFFAOYSA-N 0.000 description 2
- IRUAFPAJTYHEGV-UHFFFAOYSA-N 5-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NOC2=C1 IRUAFPAJTYHEGV-UHFFFAOYSA-N 0.000 description 2
- QLWUWVNGTYIEIX-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CCC(C4=C3)N)=NSC2=C1 QLWUWVNGTYIEIX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920002536 Scavenger resin Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 208000035548 disruptive behavior disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- ZVYSLGHPAQAHHQ-RUZDIDTESA-N n-[(2r)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]-n-(cyclopropylmethyl)acetamide Chemical compound CC(=O)N([C@H]1CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2C1)CC1CC1 ZVYSLGHPAQAHHQ-RUZDIDTESA-N 0.000 description 2
- ZVYSLGHPAQAHHQ-VWLOTQADSA-N n-[(2s)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]-n-(cyclopropylmethyl)acetamide Chemical compound CC(=O)N([C@@H]1CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2C1)CC1CC1 ZVYSLGHPAQAHHQ-VWLOTQADSA-N 0.000 description 2
- RRVCEAHEPHUWGV-UHFFFAOYSA-N n-[5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(CCCl)C=C2CC(NC(=O)C(F)(F)F)CC2=C1 RRVCEAHEPHUWGV-UHFFFAOYSA-N 0.000 description 2
- XZZBPUGIOXVBQK-UHFFFAOYSA-N n-[5-(2-chloroethyl)-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound C1=C(CCCl)C=C2C(C)(C)C(NC(=O)C)CC2=C1 XZZBPUGIOXVBQK-UHFFFAOYSA-N 0.000 description 2
- FGAQSZNFNPNKPH-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]butanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)NC(=O)CCC)=NSC2=C1 FGAQSZNFNPNKPH-UHFFFAOYSA-N 0.000 description 2
- SJDUMUAOCLZLFN-UHFFFAOYSA-N n-[6-(2-chloroacetyl)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(C(=O)CCl)C=C2C(NC(=O)C(F)(F)F)CCC2=C1 SJDUMUAOCLZLFN-UHFFFAOYSA-N 0.000 description 2
- GQRAAEYVSSQXAR-UHFFFAOYSA-N n-[6-(2-chloroacetyl)-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound ClCC(=O)C1=CC=C2C(C)(C)C(NC(=O)C)CC2=C1 GQRAAEYVSSQXAR-UHFFFAOYSA-N 0.000 description 2
- VMYZZIWQKRIMKL-UHFFFAOYSA-N n-[6-(2-chloroethyl)-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound ClCCC1=CC=C2C(C)(C)C(NC(=O)C)CC2=C1 VMYZZIWQKRIMKL-UHFFFAOYSA-N 0.000 description 2
- DBFJJDZGQHMQQY-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]-n-methylethanesulfonamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)N(C)S(=O)(=O)CC)=NSC2=C1 DBFJJDZGQHMQQY-UHFFFAOYSA-N 0.000 description 2
- WYDRRVMUXHLJAV-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]-n-ethylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(C4=CC=3)(C)C)N(CC)C(C)=O)=NSC2=C1 WYDRRVMUXHLJAV-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- HRDICAQFZAJVFM-UHFFFAOYSA-N 1-(2-chloroethyl)-2,3-dihydro-1h-indene Chemical compound C1=CC=C2C(CCCl)CCC2=C1 HRDICAQFZAJVFM-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- FNQQSDCQOLMENF-UHFFFAOYSA-N 1-methyl-2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2C(C)C(O)CC2=C1 FNQQSDCQOLMENF-UHFFFAOYSA-N 0.000 description 1
- GTDXPJJHRWOFDI-UHFFFAOYSA-N 1-methylcyclopropane-1-carbonyl chloride Chemical compound ClC(=O)C1(C)CC1 GTDXPJJHRWOFDI-UHFFFAOYSA-N 0.000 description 1
- OFUCCBIWEUKISP-UHFFFAOYSA-N 2,2,2-trifluoroacetohydrazide Chemical compound NNC(=O)C(F)(F)F OFUCCBIWEUKISP-UHFFFAOYSA-N 0.000 description 1
- FIJPHHFVOZZTTR-UHFFFAOYSA-N 2,2,3,3-tetramethylinden-1-one Chemical compound C1=CC=C2C(C)(C)C(C)(C)C(=O)C2=C1 FIJPHHFVOZZTTR-UHFFFAOYSA-N 0.000 description 1
- KMGCKSAIIHOKCX-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2CC(O)CC2=C1 KMGCKSAIIHOKCX-UHFFFAOYSA-N 0.000 description 1
- VHXUZFLRTKZTAX-UHFFFAOYSA-N 2-spiro[1,3-dioxolane-2,6'-7,8-dihydro-5h-naphthalene]-2'-ylacetic acid Chemical compound C1CC2=CC(CC(=O)O)=CC=C2CC21OCCO2 VHXUZFLRTKZTAX-UHFFFAOYSA-N 0.000 description 1
- GILLKQBOPCCOLA-UHFFFAOYSA-N 2-spiro[1,3-dioxolane-2,6'-7,8-dihydro-5h-naphthalene]-2'-ylethanol Chemical compound C1CC2=CC(CCO)=CC=C2CC21OCCO2 GILLKQBOPCCOLA-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- OINXHEDREXQARV-UHFFFAOYSA-N 3-piperazin-1-yl-1h-indazole;hydrochloride Chemical compound Cl.C1CNCCN1C1=NNC2=CC=CC=C12 OINXHEDREXQARV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- PGQXWARAQYMLLA-UHFFFAOYSA-N 5-[1-hydroxy-2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CC(O)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NNC2=C1 PGQXWARAQYMLLA-UHFFFAOYSA-N 0.000 description 1
- FQODIUNNNNZXEV-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-(methylamino)ethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=C2C(C)(C)C(O)C(C)(C)C2=CC(C(CN2CCN(CC2)C=2C3=CC=CC=C3SN=2)NC)=C1 FQODIUNNNNZXEV-UHFFFAOYSA-N 0.000 description 1
- CDCRBEUVUJTPRT-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-(methylamino)ethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=C2C(C)(C)C(=O)C(C)(C)C2=CC(C(CN2CCN(CC2)C=2C3=CC=CC=C3SN=2)NC)=C1 CDCRBEUVUJTPRT-UHFFFAOYSA-N 0.000 description 1
- XCUKEEMTTNZQAA-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-chloroethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(Cl)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 XCUKEEMTTNZQAA-UHFFFAOYSA-N 0.000 description 1
- PFUZYXSTRKVJSV-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-fluoroethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CC(F)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NSC2=C1 PFUZYXSTRKVJSV-UHFFFAOYSA-N 0.000 description 1
- CNJGNCWYMDMRRV-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-fluoroethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(F)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 CNJGNCWYMDMRRV-UHFFFAOYSA-N 0.000 description 1
- MJHWDOGLPQDSDM-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]-1-hydroxyethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CC(O)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NSC2=C1 MJHWDOGLPQDSDM-UHFFFAOYSA-N 0.000 description 1
- LYRQEWZJNAEVOD-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]acetyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(=O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 LYRQEWZJNAEVOD-UHFFFAOYSA-N 0.000 description 1
- QIJQEUCKNXIING-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(N)C(C4=CC=3)(C)C)=NSC2=C1 QIJQEUCKNXIING-UHFFFAOYSA-N 0.000 description 1
- CPJPXEFYRZLIQC-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)N)=NSC2=C1 CPJPXEFYRZLIQC-UHFFFAOYSA-N 0.000 description 1
- DBCBYVGUBDLPPQ-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n,1,1,3,3-pentamethyl-2h-inden-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C(C)(C)C(C(C4=C3)(C)C)NC)=NSC2=C1 DBCBYVGUBDLPPQ-UHFFFAOYSA-N 0.000 description 1
- KYKRLQUIRZOWHX-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n-ethyl-3,3-dimethyl-1,2-dihydroinden-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(C(C4=C3)(C)C)NCC)=NSC2=C1 KYKRLQUIRZOWHX-UHFFFAOYSA-N 0.000 description 1
- ZIHUPKACMFQYHS-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-chloroethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CC(Cl)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NOC2=C1 ZIHUPKACMFQYHS-UHFFFAOYSA-N 0.000 description 1
- UHOMPRNYRGUDRH-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-ethoxyethyl]-1,1,3,3-tetramethylinden-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C2C(C)(C)C(=O)C(C)(C)C2=CC(C(CN2CCN(CC2)C=2C3=CC=CC=C3ON=2)OCC)=C1 UHOMPRNYRGUDRH-UHFFFAOYSA-N 0.000 description 1
- SGJHTRSRIGXTSC-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-hydroxyethyl]-1,1,3,3-tetramethyl-2h-inden-2-ol Chemical compound C1=CC=C2C(N3CCN(CC3)CC(O)C=3C=C4C(C)(C)C(O)C(C4=CC=3)(C)C)=NOC2=C1 SGJHTRSRIGXTSC-UHFFFAOYSA-N 0.000 description 1
- IUBPNHLGCAJSRF-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-hydroxyethyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 IUBPNHLGCAJSRF-UHFFFAOYSA-N 0.000 description 1
- DKLFLXQFHVMKPG-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]acetyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(=O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 DKLFLXQFHVMKPG-UHFFFAOYSA-N 0.000 description 1
- XTWBGQITVHXZSK-UHFFFAOYSA-N 5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethylinden-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 XTWBGQITVHXZSK-UHFFFAOYSA-N 0.000 description 1
- IGHIPIIRGDRHQK-UHFFFAOYSA-N 5-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]acetyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CC(=O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NNC2=C1 IGHIPIIRGDRHQK-UHFFFAOYSA-N 0.000 description 1
- KZBVFVYRVBGUQO-UHFFFAOYSA-N 5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,1,3,3-tetramethylinden-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NSC2=C1 KZBVFVYRVBGUQO-UHFFFAOYSA-N 0.000 description 1
- QUDNKQBVGBTWDT-UHFFFAOYSA-N 5-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-chloropropyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(Cl)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 QUDNKQBVGBTWDT-UHFFFAOYSA-N 0.000 description 1
- DVZGUFZNFFWEAA-UHFFFAOYSA-N 5-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]-1-hydroxypropyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 DVZGUFZNFFWEAA-UHFFFAOYSA-N 0.000 description 1
- YPARHEXFGOHRFK-UHFFFAOYSA-N 5-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propanoyl]-1,1,3,3-tetramethylinden-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC(=O)C=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 YPARHEXFGOHRFK-UHFFFAOYSA-N 0.000 description 1
- WEDFVOXOWHQQHI-UHFFFAOYSA-N 5-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-1,1,3,3-tetramethylinden-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)C(=O)C(C4=CC=3)(C)C)=NOC2=C1 WEDFVOXOWHQQHI-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- LXUWFUMTUVPMSM-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n-ethyl-3,3-dimethyl-1,2-dihydroinden-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(C4=CC=3)(C)C)NCC)=NSC2=C1 LXUWFUMTUVPMSM-UHFFFAOYSA-N 0.000 description 1
- FVPWMFINOZQAEU-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n-ethyl-3,3-dimethyl-1,2-dihydroinden-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(C4=CC=3)(C)C)NCC)=NSC2=C1 FVPWMFINOZQAEU-UHFFFAOYSA-N 0.000 description 1
- NKFCVJDTDIPQLM-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-n-methyl-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NC)=NSC2=C1 NKFCVJDTDIPQLM-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- QBCDSZVZGNPLKS-UHFFFAOYSA-N C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NS(=O)(=O)CCC)=NSC2=C1 Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NS(=O)(=O)CCC)=NSC2=C1 QBCDSZVZGNPLKS-UHFFFAOYSA-N 0.000 description 1
- HVYMHWFJJOOQPO-UHFFFAOYSA-N C1CC2=CC=CC=C2C1N(C3CCC4=CC=CC=C34)NC(=O)C(F)(F)F Chemical compound C1CC2=CC=CC=C2C1N(C3CCC4=CC=CC=C34)NC(=O)C(F)(F)F HVYMHWFJJOOQPO-UHFFFAOYSA-N 0.000 description 1
- PDHRKEDNYSGKML-UHFFFAOYSA-N CC(=O)N(CS(=O)(=O)O)C1C(C2=C(C1(C)C)C=C(C=C2)CCN3CCN(CC3)C4=NOC5=CC=CC=C54)(C)C Chemical compound CC(=O)N(CS(=O)(=O)O)C1C(C2=C(C1(C)C)C=C(C=C2)CCN3CCN(CC3)C4=NOC5=CC=CC=C54)(C)C PDHRKEDNYSGKML-UHFFFAOYSA-N 0.000 description 1
- XAXCXPXGIZSIPI-UHFFFAOYSA-N CC1(C(C(C2=C1C=CC(=C2)CCC(N3CCN(CC3)C4=NSC5=CC=CC=C54)O)(C)C)O)C Chemical compound CC1(C(C(C2=C1C=CC(=C2)CCC(N3CCN(CC3)C4=NSC5=CC=CC=C54)O)(C)C)O)C XAXCXPXGIZSIPI-UHFFFAOYSA-N 0.000 description 1
- RQAIFPCZIGRXPD-UHFFFAOYSA-N CC1(C2=CC=CC(=C2C(C1=O)(C)C)C(CCN3CCN(CC3)C4=NOC5=CC=CC=C54)O)C Chemical compound CC1(C2=CC=CC(=C2C(C1=O)(C)C)C(CCN3CCN(CC3)C4=NOC5=CC=CC=C54)O)C RQAIFPCZIGRXPD-UHFFFAOYSA-N 0.000 description 1
- JGVOAZVHNOJMKP-UHFFFAOYSA-N CC1(CC(C2=C1C=CC(=C2)C(=O)CCN3CCN(CC3)C4=NSC5=CC=CC=C54)(C)C)C Chemical compound CC1(CC(C2=C1C=CC(=C2)C(=O)CCN3CCN(CC3)C4=NSC5=CC=CC=C54)(C)C)C JGVOAZVHNOJMKP-UHFFFAOYSA-N 0.000 description 1
- VSTDMONAVWFDRI-UHFFFAOYSA-N CC1(CC(C2=C1C=CC(=C2)C(CN3CCN(CC3)C4=NSC5=CC=CC=C54)Cl)(C)C)C Chemical compound CC1(CC(C2=C1C=CC(=C2)C(CN3CCN(CC3)C4=NSC5=CC=CC=C54)Cl)(C)C)C VSTDMONAVWFDRI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- SRMVZRXBHVEHPS-UHFFFAOYSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)N)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)N)=NSC2=C1 SRMVZRXBHVEHPS-UHFFFAOYSA-N 0.000 description 1
- HLQGSNCOZHDBCV-FTBISJDPSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)N(C)C(C)=O)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)N(C)C(C)=O)=NSC2=C1 HLQGSNCOZHDBCV-FTBISJDPSA-N 0.000 description 1
- AVQFAFIVPNCHAQ-UHFFFAOYSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)=O)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)=O)=NSC2=C1 AVQFAFIVPNCHAQ-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical class OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- PSCWEOBPFSNHCG-HSZRJFAPSA-N N-[(2R)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1H-inden-2-yl]-N-ethylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@H](CC4=C3)N(CC)C(C)=O)=NSC2=C1 PSCWEOBPFSNHCG-HSZRJFAPSA-N 0.000 description 1
- HLQGSNCOZHDBCV-VZYDHVRKSA-N N-[(2R)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1H-inden-2-yl]-N-methylacetamide hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@H](CC4=C3)N(C)C(C)=O)=NSC2=C1 HLQGSNCOZHDBCV-VZYDHVRKSA-N 0.000 description 1
- PSCWEOBPFSNHCG-QHCPKHFHSA-N N-[(2S)-5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1H-inden-2-yl]-N-ethylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C[C@@H](CC4=C3)N(CC)C(C)=O)=NSC2=C1 PSCWEOBPFSNHCG-QHCPKHFHSA-N 0.000 description 1
- BELCKSRGKSZZEE-UHFFFAOYSA-N N-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]cyclopentanecarboxamide Chemical compound C1CCC(C1)C(=O)NC2CCC3=C(C2)C=CC(=C3)CCN4CCN(CC4)C5=NSC6=CC=CC=C65 BELCKSRGKSZZEE-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- XBQQLLSJECNALZ-XVNBXDOJSA-N O=C(C(F)(F)F)/C=C/CC1Cc2ccccc2C1 Chemical compound O=C(C(F)(F)F)/C=C/CC1Cc2ccccc2C1 XBQQLLSJECNALZ-XVNBXDOJSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- RFHPXPUMOWDMLD-UHFFFAOYSA-N [5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-yl] methanesulfonate Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(OS(C)(=O)=O)C(C4=CC=3)(C)C)=NOC2=C1 RFHPXPUMOWDMLD-UHFFFAOYSA-N 0.000 description 1
- WBYJBQOZQXYSQM-UHFFFAOYSA-N [5-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,1,3,3-tetramethyl-2h-inden-2-yl] methanesulfonate Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)C(OS(C)(=O)=O)C(C4=CC=3)(C)C)=NSC2=C1 WBYJBQOZQXYSQM-UHFFFAOYSA-N 0.000 description 1
- FRSNGSRJMAQWSD-UHFFFAOYSA-M [Cl-].[Mg+]CCC(C)C1=CC=CC=C1 Chemical compound [Cl-].[Mg+]CCC(C)C1=CC=CC=C1 FRSNGSRJMAQWSD-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 1
- 229950003678 flesinoxan Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- IAYVMLBSLIXECH-UHFFFAOYSA-N methanesulfonic acid 1,1,3,3-tetramethylinden-2-one Chemical compound CS(O)(=O)=O.CC1(C)C(=O)C(C)(C)c2ccccc12 IAYVMLBSLIXECH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- XRPITCBWOUOJTH-UHFFFAOYSA-N n,n-diethylpyridin-2-amine Chemical compound CCN(CC)C1=CC=CC=N1 XRPITCBWOUOJTH-UHFFFAOYSA-N 0.000 description 1
- YUPHAYFQAVLCRV-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)-2,2,2-trifluoroacetamide Chemical compound C1=CC=C2C(NC(=O)C(F)(F)F)CCC2=C1 YUPHAYFQAVLCRV-UHFFFAOYSA-N 0.000 description 1
- ADXYZWCRKREQFD-UHFFFAOYSA-N n-(3,3-dimethyl-1h-inden-2-ylidene)hydroxylamine Chemical compound C1=CC=C2C(C)(C)C(=NO)CC2=C1 ADXYZWCRKREQFD-UHFFFAOYSA-N 0.000 description 1
- IYMLYMUNLKBLSU-CYBMUJFWSA-N n-[(2r)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]-1,2-oxazole-5-carboxamide Chemical compound N([C@@H]1CC2=CC=C(C=C2C1)CCCl)C(=O)C1=CC=NO1 IYMLYMUNLKBLSU-CYBMUJFWSA-N 0.000 description 1
- WEKJSPBSABYNNP-CQSZACIVSA-N n-[(2r)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]-2-methylpropanamide Chemical compound C1=C(CCCl)C=C2C[C@H](NC(=O)C(C)C)CC2=C1 WEKJSPBSABYNNP-CQSZACIVSA-N 0.000 description 1
- XLOWBBKDFARSAS-CYBMUJFWSA-N n-[(2r)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]acetamide Chemical compound C1=C(CCCl)C=C2C[C@H](NC(=O)C)CC2=C1 XLOWBBKDFARSAS-CYBMUJFWSA-N 0.000 description 1
- LDODWMYYEYPXKA-CQSZACIVSA-N n-[(2r)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]butanamide Chemical compound C1=C(CCCl)C=C2C[C@H](NC(=O)CCC)CC2=C1 LDODWMYYEYPXKA-CQSZACIVSA-N 0.000 description 1
- HEKQJEPFZAIAOX-CQSZACIVSA-N n-[(2r)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]cyclopropanecarboxamide Chemical compound N([C@@H]1CC2=CC=C(C=C2C1)CCCl)C(=O)C1CC1 HEKQJEPFZAIAOX-CQSZACIVSA-N 0.000 description 1
- IYMLYMUNLKBLSU-ZDUSSCGKSA-N n-[(2s)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]-1,2-oxazole-5-carboxamide Chemical compound N([C@H]1CC2=CC=C(C=C2C1)CCCl)C(=O)C1=CC=NO1 IYMLYMUNLKBLSU-ZDUSSCGKSA-N 0.000 description 1
- WEKJSPBSABYNNP-AWEZNQCLSA-N n-[(2s)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]-2-methylpropanamide Chemical compound C1=C(CCCl)C=C2C[C@@H](NC(=O)C(C)C)CC2=C1 WEKJSPBSABYNNP-AWEZNQCLSA-N 0.000 description 1
- HEKQJEPFZAIAOX-AWEZNQCLSA-N n-[(2s)-5-(2-chloroethyl)-2,3-dihydro-1h-inden-2-yl]cyclopropanecarboxamide Chemical compound N([C@H]1CC2=CC=C(C=C2C1)CCCl)C(=O)C1CC1 HEKQJEPFZAIAOX-AWEZNQCLSA-N 0.000 description 1
- BFWOJPJNKPDKPQ-UHFFFAOYSA-N n-[4-(2-chloroacetyl)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=CC=C(C(=O)CCl)C2=C1C(NC(=O)C(F)(F)F)CC2 BFWOJPJNKPDKPQ-UHFFFAOYSA-N 0.000 description 1
- IWWWBINUWFICRY-UHFFFAOYSA-N n-[5-(2-chloroacetyl)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound ClCC(=O)C1=CC=C2C(NC(=O)C(F)(F)F)CCC2=C1 IWWWBINUWFICRY-UHFFFAOYSA-N 0.000 description 1
- JKJTYNIDZPMHMC-UHFFFAOYSA-N n-[5-(2-chloroacetyl)-2,3-dihydro-1h-inden-2-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(C(=O)CCl)C=C2CC(NC(=O)C(F)(F)F)CC2=C1 JKJTYNIDZPMHMC-UHFFFAOYSA-N 0.000 description 1
- UXVXIADJHZHLPN-UHFFFAOYSA-N n-[5-(2-chloroacetyl)-3,3-dimethyl-1,2-dihydroinden-2-yl]acetamide Chemical compound C1=C(C(=O)CCl)C=C2C(C)(C)C(NC(=O)C)CC2=C1 UXVXIADJHZHLPN-UHFFFAOYSA-N 0.000 description 1
- WZKYRBHMAAHXNT-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(CC4=C3)NC(=O)C)=NSC2=C1 WZKYRBHMAAHXNT-UHFFFAOYSA-N 0.000 description 1
- UFSSPCIBOBOIGT-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]-n-ethylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(C(C4=C3)(C)C)N(CC)C(C)=O)=NSC2=C1 UFSSPCIBOBOIGT-UHFFFAOYSA-N 0.000 description 1
- JAVSZMRDEBMRTO-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]-n-ethylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CC(C(C4=C3)(C)C)N(CC)C(C)=O)=NSC2=C1 JAVSZMRDEBMRTO-UHFFFAOYSA-N 0.000 description 1
- AFRZLYMPQAPYKR-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4C(C)(C)C(C(C4=C3)(C)C)NC(=O)C)=NOC2=C1 AFRZLYMPQAPYKR-UHFFFAOYSA-N 0.000 description 1
- DBCANESUGAYNID-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethyl-2h-inden-2-yl]methanesulfonamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(NS(C)(=O)=O)C(C4=CC=3)(C)C)=NOC2=C1 DBCANESUGAYNID-UHFFFAOYSA-N 0.000 description 1
- BEMSNUXDOGZWCF-UHFFFAOYSA-N n-[5-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,1,3,3-tetramethylinden-2-ylidene]hydroxylamine Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(=NO)C(C4=CC=3)(C)C)=NOC2=C1 BEMSNUXDOGZWCF-UHFFFAOYSA-N 0.000 description 1
- ZJXFRHFTUROLML-UHFFFAOYSA-N n-[6-(2-chloroethyl)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(CCCl)C=C2C(NC(=O)C(F)(F)F)CCC2=C1 ZJXFRHFTUROLML-UHFFFAOYSA-N 0.000 description 1
- HLESJUBIPYTAAX-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]-n-methylacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)N(C)C(C)=O)=NSC2=C1 HLESJUBIPYTAAX-UHFFFAOYSA-N 0.000 description 1
- YPIBWOOYROQBFQ-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NC(=O)C)=NSC2=C1 YPIBWOOYROQBFQ-UHFFFAOYSA-N 0.000 description 1
- DHLZOCXDGHARPO-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]benzenesulfonamide Chemical compound C1CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2CC1NS(=O)(=O)C1=CC=CC=C1 DHLZOCXDGHARPO-UHFFFAOYSA-N 0.000 description 1
- ZRQBXWRSPAWCTG-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl]butanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCC(CC4=CC=3)NC(=O)CCC)=NSC2=C1 ZRQBXWRSPAWCTG-UHFFFAOYSA-N 0.000 description 1
- ZUJPXZIUFHGAJI-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4CCC(C4=C3)NC(=O)C(F)(F)F)=NSC2=C1 ZUJPXZIUFHGAJI-UHFFFAOYSA-N 0.000 description 1
- HESQZYBWHHIHHT-UHFFFAOYSA-N n-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,2-dihydroinden-2-yl]-n-ethylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(C4=CC=3)(C)C)N(CC)C(C)=O)=NSC2=C1 HESQZYBWHHIHHT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52785203P | 2003-12-08 | 2003-12-08 | |
| US60/527,852 | 2003-12-08 | ||
| US53109603P | 2003-12-19 | 2003-12-19 | |
| US60/531,096 | 2003-12-19 | ||
| PCT/IB2004/003898 WO2005056540A1 (en) | 2003-12-08 | 2004-11-26 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513197A true JP2007513197A (ja) | 2007-05-24 |
| JP2007513197A6 JP2007513197A6 (ja) | 2007-09-06 |
| JP2007513197A5 JP2007513197A5 (enExample) | 2008-01-24 |
Family
ID=34811295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006543635A Pending JP2007513197A (ja) | 2003-12-08 | 2004-11-26 | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050282819A1 (enExample) |
| EP (1) | EP1697334A1 (enExample) |
| JP (1) | JP2007513197A (enExample) |
| AR (1) | AR047325A1 (enExample) |
| BR (1) | BRPI0416739A (enExample) |
| CA (1) | CA2548447A1 (enExample) |
| NL (1) | NL1027680C2 (enExample) |
| PA (1) | PA8619301A1 (enExample) |
| PE (1) | PE20050862A1 (enExample) |
| TW (1) | TW200524922A (enExample) |
| UY (1) | UY28656A1 (enExample) |
| WO (1) | WO2005056540A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| WO2007076601A1 (en) * | 2006-01-03 | 2007-07-12 | Clera Inc. | Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof |
| TW200804347A (en) * | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
| CN101448803A (zh) * | 2006-03-17 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 用作5-ht6调节剂的四氢萘 |
| KR20090040352A (ko) | 2006-07-31 | 2009-04-23 | 얀센 파마슈티카 엔.브이. | 유로텐신 ⅱ 수용체 길항제 |
| WO2010017105A1 (en) * | 2008-08-02 | 2010-02-11 | Janssen Pharmaceutica N.V. | Urotensin ii receptor antagonists |
| UY32442A (es) | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
| UY32443A (es) | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento. |
| CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0542136A1 (en) * | 1991-11-05 | 1993-05-19 | Hoechst-Roussel Pharmaceuticals Incorporated | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| WO2001017993A1 (en) * | 1999-09-09 | 2001-03-15 | EGIS Gyógyszergyár Rt. | Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient |
| EP1188747A1 (en) * | 1999-05-24 | 2002-03-20 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| FR2654104B1 (fr) * | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2671350A1 (fr) * | 1991-01-08 | 1992-07-10 | Adir | Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant. |
| MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| US6242450B1 (en) * | 1998-07-27 | 2001-06-05 | Eli Lilly And Company | 5-HT1F antagonists |
| BR0314393A (pt) * | 2002-09-17 | 2005-07-19 | Warner Lambert Co | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia |
| MXPA05002003A (es) * | 2002-09-26 | 2005-08-03 | Warner Lambert Co | Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia. |
-
2004
- 2004-11-26 JP JP2006543635A patent/JP2007513197A/ja active Pending
- 2004-11-26 EP EP04799000A patent/EP1697334A1/en not_active Withdrawn
- 2004-11-26 WO PCT/IB2004/003898 patent/WO2005056540A1/en not_active Ceased
- 2004-11-26 BR BRPI0416739-2A patent/BRPI0416739A/pt not_active IP Right Cessation
- 2004-11-26 CA CA002548447A patent/CA2548447A1/en not_active Abandoned
- 2004-12-06 AR ARP040104547A patent/AR047325A1/es unknown
- 2004-12-06 PE PE2004001197A patent/PE20050862A1/es not_active Application Discontinuation
- 2004-12-06 UY UY28656A patent/UY28656A1/es not_active Application Discontinuation
- 2004-12-07 NL NL1027680A patent/NL1027680C2/nl not_active IP Right Cessation
- 2004-12-07 PA PA20048619301A patent/PA8619301A1/es unknown
- 2004-12-07 TW TW093137739A patent/TW200524922A/zh unknown
- 2004-12-08 US US11/007,486 patent/US20050282819A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0542136A1 (en) * | 1991-11-05 | 1993-05-19 | Hoechst-Roussel Pharmaceuticals Incorporated | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| EP1188747A1 (en) * | 1999-05-24 | 2002-03-20 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
| WO2001017993A1 (en) * | 1999-09-09 | 2001-03-15 | EGIS Gyógyszergyár Rt. | Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| UY28656A1 (es) | 2005-07-29 |
| NL1027680C2 (nl) | 2005-11-30 |
| US20050282819A1 (en) | 2005-12-22 |
| PE20050862A1 (es) | 2005-12-17 |
| AR047325A1 (es) | 2006-01-18 |
| CA2548447A1 (en) | 2005-06-23 |
| TW200524922A (en) | 2005-08-01 |
| NL1027680A1 (nl) | 2005-06-09 |
| EP1697334A1 (en) | 2006-09-06 |
| WO2005056540A1 (en) | 2005-06-23 |
| BRPI0416739A (pt) | 2007-01-16 |
| PA8619301A1 (es) | 2005-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1836179T3 (en) | PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS | |
| JP5798115B2 (ja) | 置換ヒドロキサム酸およびその使用 | |
| WO2020146612A1 (en) | Esters and carbamates as modulators of sodium channels | |
| JP2010529117A (ja) | 代謝型グルタミン酸受容体オキサジアゾールリガンドおよびそれらの増強剤としての使用 | |
| KR101107807B1 (ko) | 5-ｈｔ(5ａ) 수용체 길항제로서의 2-아미노퀴놀린 | |
| WO2010002802A1 (en) | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity | |
| AU2019459552A1 (en) | Dihydro-pyrrolo-pyrimidine selective JAK2 inhibitor | |
| RU2169147C2 (ru) | ПРОИЗВОДНЫЕ АМИДОВ КАРБОНОВЫХ КИСЛОТ С ГЕТЕРОЦИКЛИЧЕСКИМИ ЗАМЕСТИТЕЛЯМИ И КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНГИБИРОВАТЬ 5-HT1А, И/ИЛИ α1, И/ИЛИ α2A, И/ИЛИ α2D, И/ИЛИ D2 РЕЦЕПТОРЫ | |
| RU2196140C2 (ru) | Производные оксазолидинонов в качестве антагонистов 5-ht2а, способ их получения и фармацевтическая композиция | |
| CN101602741A (zh) | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 | |
| CA2926754C (en) | Piperazine derivatives and the use thereof as medicament | |
| WO2010137620A1 (ja) | フェノキシエチルアミン誘導体 | |
| JP2007513197A (ja) | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 | |
| JP2007513197A6 (ja) | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 | |
| WO2002006231A1 (en) | Serotonin reuptake inhibitors | |
| US20090306052A1 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| WO2008116831A1 (en) | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor | |
| WO2013118845A1 (ja) | 複素環化合物およびその用途 | |
| SK286977B6 (sk) | Morfolínové deriváty, spôsob ich prípravy a farmaceutické prostriedky obsahujúce tieto zlúčeniny a ich použitie | |
| JP2008509961A (ja) | ５−ｈｔ７受容体アンタゴニスト | |
| KR101070176B1 (ko) | Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물 | |
| CN114929681A (zh) | 二环cx3cr1受体激动剂 | |
| MXPA05003658A (es) | Derivados de piperazina sustituidos con oxindol. | |
| MXPA06006033A (en) | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | |
| JP2007517855A (ja) | セロトニン及びノルアドレナリン再取込み阻害剤としての活性を示すピペラジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110510 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111018 |